These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32121123)

  • 1. Cognitive Abilities of Dogs with Mucopolysaccharidosis I: Learning and Memory.
    Provoost L; Siracusa C; Stefanovski D; Che Y; Li M; Casal M
    Animals (Basel); 2020 Feb; 10(3):. PubMed ID: 32121123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
    Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
    Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extensive spatial training does not negate age differences in response latency.
    Nippak PM; Ikeda-Douglas C; Milgram NW
    Brain Res; 2006 Jan; 1070(1):171-88. PubMed ID: 16460702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
    Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
    Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of the molecular lesion causing mucopolysaccharidosis type I in cats.
    He X; Li CM; Simonaro CM; Wan Q; Haskins ME; Desnick RJ; Schuchman EH
    Mol Genet Metab; 1999 Jun; 67(2):106-12. PubMed ID: 10356309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation of the relationship between response latency across several cognitive tasks in the beagle dog.
    Nippak PM; Milgram NW
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):371-7. PubMed ID: 15795045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
    Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM
    Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogate Cerebrospinal Fluid Biomarkers for Assessing the Efficacy of Gene Therapy in Hurler Syndrome.
    Haseloff RF; Trudel S; Birke R; Schümann M; Krause E; Gomila C; Heard JM; Blasig IE; Ausseil J
    Front Neurol; 2021; 12():640547. PubMed ID: 34054689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.
    Oussoren E; Keulemans J; van Diggelen OP; Oemardien LF; Timmermans RG; van der Ploeg AT; Ruijter GJ
    Mol Genet Metab; 2013 Aug; 109(4):377-81. PubMed ID: 23786846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
    Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
    Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.
    Hinderer C; Bell P; Louboutin JP; Zhu Y; Yu H; Lin G; Choa R; Gurda BL; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Tarantal AF; Casal ML; Haskins ME; Wilson JM
    Mol Ther; 2015 Aug; 23(8):1298-1307. PubMed ID: 26022732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA.
    Roberts AL; Rees MH; Klebe S; Fletcher JM; Byers S
    Mol Genet Metab; 2007; 92(1-2):115-21. PubMed ID: 17681480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy.
    Traas AM; Wang P; Ma X; Tittiger M; Schaller L; O'donnell P; Sleeper MM; Vite C; Herati R; Aguirre GD; Haskins M; Ponder KP
    Mol Ther; 2007 Aug; 15(8):1423-31. PubMed ID: 17519893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucopolysaccharidosis type I.
    Wraith JE; Jones S
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of mucopolysaccharidosis type I heterozygotes based on the biochemical characteristics of leukocyte alpha-L-iduronidase.
    Mandelli J; Wajner A; Pires RF; Giugliani R; Coelho JC
    Arch Med Res; 2002; 33(1):20-4. PubMed ID: 11825626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant encapsulated cells overexpressing alpha-L-iduronidase correct enzyme deficiency in human mucopolysaccharidosis type I cells.
    Baldo G; Quoos Mayer F; Burin M; Carrillo-Farga J; Matte U; Giugliani R
    Cells Tissues Organs; 2012; 195(4):323-9. PubMed ID: 21778683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors.
    Di Natale P; Di Domenico C; Villani GR; Lombardo A; Follenzi A; Naldini L
    Eur J Biochem; 2002 Jun; 269(11):2764-71. PubMed ID: 12047386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system.
    Schuh RS; Poletto É; Pasqualim G; Tavares AMV; Meyer FS; Gonzalez EA; Giugliani R; Matte U; Teixeira HF; Baldo G
    J Control Release; 2018 Oct; 288():23-33. PubMed ID: 30170069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous implantation of microencapsulated cells overexpressing α-L-iduronidase for mucopolysaccharidosis type I treatment.
    Lizzi Lagranha V; Zambiasi Martinelli B; Baldo G; Ávila Testa G; Giacomet de Carvalho T; Giugliani R; Matte U
    J Mater Sci Mater Med; 2017 Mar; 28(3):43. PubMed ID: 28150116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
    Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB
    Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.